All News
EULAR 2023 – Day 3 Report
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Read Article
AI in RA: the story grows along the patient pathway
The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions, including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.
Read Article
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies.
@Janetbirdope
https://t.co/IQ9bxbTSV4 https://t.co/jVYOphxpAE
Links:
Dr. John Cush RheumNow ( View Tweet)
Supervised 12 weeks High-intensity interval training program
Improves Vo2 peak in IA patients
But does not improve pain or fatigue
It is disappointing but it is also a small study w/ n=30 pts in each group.
It is unclear if the type of exercise has an impact on outcome https://t.co/Plk7sflrh5
Aurelie Najm AurelieRheumo ( View Tweet)
What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists?
They don't seem to do great yet!
600 new pts, outw/ 36% dvlpd IA
IA Sens 62% Spe 47%
Tool Sens 66% Spe 54%
More work needed to implement these in practice
#EULAR23 @Rheumnow
Aurelie Najm AurelieRheumo ( View Tweet)
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/PPI1fvwLAf https://t.co/qMXMsbpwl3
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Adherence to TNFi follows different trajectories
Cluster 1: “moderate then high” 51%
Cluster 2: “moderate then low” 20%
Cluster 3: “low adherence, to discontinuation” 18%
Cluster 4: “low then high adherence” 11%
Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
Aurelie Najm AurelieRheumo ( View Tweet)
Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK
Dr. Antoni Chan synovialjoints ( View Tweet)
Late Breaker - Cardiorespiratory fitness increased in patients with IJD after 12 weeks of supervised
HIIT and effect maintained at 6 months. No significant differences in pain and fatigue vs control. HIIT is a viable intervention Norden K Abst#LB0007 #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
2023 update @EULAR recommendations imaging in GCA
What's new:
1. US = first line imaging test
2. Axillary arteries should be included in standard examination
3. Alternative imaging FDG-PET or MRI
4. Takayasu: MRI preferred CT or FDG-PET alternatives
@Rheumnow #EULAR23 LB0008 https://t.co/rGPfOPX1gI
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Clinical Highlights. CTD: OP0240 Open label study (N=26) showed stabilisation/improvement in FVC in patients with #ILD treated either Tacrolimus vs MMF. No efficacy difference between both therapies @RheumNow https://t.co/d3rCzNgYHK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324 @RheumNow Small differences but maybe a script to go south is the right Rx! https://t.co/tjd6FjEHij
Janet Pope Janetbirdope ( View Tweet)
Which bDMARD first in PsA?
2023 @eular_org recommendation: no preferred order. All are equal in its eyes
#EULAR2023 @RheumNow https://t.co/6HNNamAj1J
David Liew drdavidliew ( View Tweet)
It might not be perfect, but it’s just great to have a dynamic poster floor back #EULAR2023. The heartbeat of the meeting!
(this was near the end on the last day - it’s been properly hectic throughout) @RheumNow https://t.co/jPGO5dylvg
David Liew drdavidliew ( View Tweet)
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew drdavidliew ( View Tweet)
Using app for self-management in clinical care. There is a need to have continued engagement both patients and clinicians, constantly evolve the product, adapt to the changing needs of patients eg.pre and post pandemic, #WIIFM? @AurelieRheumo @ProfYelizPrior #EULAR2023 @RheumNow https://t.co/5RKog9EMsV
Dr. Antoni Chan synovialjoints ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS
#EULAR2023 poster https://t.co/dgGY496dbh
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
